Expert Interview
A Second View: Discussing Janssen/Protagonist Therapeutics recent Icotrokinra Results Showing 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Ticker(s): JNJ, PTGXInstitution: Bryn Mawr Medical
- Dermatologist and clinical faculty at the University of Pennsylvania
- Treats 100+ adolescent patients with moderate to severe plaque psoriasis annually
- Very familiar with the recent clinical data for icotrokinra, including its PASI 100 results and oral dosing profile
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
